Methods for treating crohn's and other TNF associated diseases

• US 20040002546A1
• Filed: 09/14/2002
• Published: 01/01/2004
• Est. Priority Date: 09/15/2001
• Status: Abandoned Application

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Altschuler, Eric
• Application Number:
  US10/244,037
• Publication Number:
  US 20040002546A1
• Time in Patent Office: Days
• US Class Current: 514/649
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Abstract

A new method employing a known compound, bupropion hydrochloride (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride, and its analogues, in a new use for the treatment of TNF-related disorders is described.

Claims

1. A method for treating Crohn'"'"'s Disease in patients without causing beta-andrenergic receptor down-regulation, comprising

administering bupropion in an effective dose to alleviate or eliminate symptoms and gut pathology, and

monitoring the patient'"'"'s CDAI level wherein the dose is adjusted according to degree of alleviation and elimination of symptoms

2. The method according to claim 1, wherein the effective dose is in the range of 150 mg BID to 150 mg TID for an adult patient.

8. The method according to claim 1, wherein the anemia treated is related to chronic disease.

3. A method for treating TNF associated diseases without causing beta-andrenergic receptor down-regulation, comprising

administering bupropion in an effective dose to alleviate or eliminate TNF associated disease symptoms and pathology;

and

monitoring the patient'"'"'s response wherein the dose is adjusted according to degree of alleviation and elimination of the symptoms and pathology

4. A method for treating rheumatoid arthritis in patients without causing beta-andrenergic receptor down-regulation, comprising.

administering bupropion in an effective dose to alleviate or eliminate symptoms and pathology;

and

monitoring the patient'"'"'s response wherein the dose is adjusted according to degree of alleviation and elimination of symptoms.

5. A method for treating psoriasis in patients without causing beta-andrenergic receptor down-regulation, comprising.

administering bupropion in an effective dose to alleviate or eliminate symptoms and pathology, and

monitoring the patient'"'"'s response wherein the dose is adjusted according to degree of alleviation and elimination of symptoms

6. A method for treating IgA nephropathy in patients without causing beta-andrenergic receptor down-regulation, comprising.

administering bupropion in an effective dose to alleviate or eliminate symptoms and pathology, and

monitoring the patient'"'"'s response wherein the dose is adjusted according to degree of alleviation and elimination of symptoms

7. A method for treating anemia in patients without causing beta-andrenergic receptor down-regulation, comprising:

administering bupropion in an effective dose to alleviate or eliminate symptoms and pathology, and

monitoring the patient'"'"'s response wherein the dose is adjusted according to degree of alleviation and elimination of symptoms

9. A method for treating myelodysplasia in patients without causing beta-andrenergic receptor down-regulation, comprising.

administering bupropion in an effective dose to alleviate or eliminate symptoms and pathology;

and

monitoring the patient'"'"'s response wherein the dose is adjusted according to degree of alleviation and elimination of symptoms